Tengion

Tengion, Inc. is a medicine company, which engages in discovering, developing, manufacturing and commercializing neo-organs and products. The company is headquartered in Winston-Salem, North Carolina and currently employs 25 full-time employees. The company went IPO on 2010-04-09. The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells. The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.